The BridgeTech Program is a national professional development program that trains researchers and entrepreneurs on how to effectively navigate the medtech commercialisation pathway.
Convened and administered by QUT, the BridgeTech Program involves a consortium of partners including medtech companies, universities and industry associations. Leveraging off the industry expertise and global connections that the consortium offers, the BridgeTech Program equips participants with the necessary skills and networks needed to take new medtech to market.
Launched in 2018, the program selects up to 100 participants annually from across Australia to take part in face-to-face and online training, presented through an interactive, self-paced platform. The BridgeTech Program provides specific training on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that are essential to medtech commercialisation. Involving online learning and materials, webinars, a touring speaker series and culminating in the 3-day BridgeTech Symposium, the program has a 1-year duration that is accessible from anywhere around Australia.
Selected as part of the MTPConnect Project Fund Program in 2018 & 2019, the BridgeTech Program was awarded industry matched funding to deliver a unique education program that enables participants to successfully navigate the commercialisation of Australian medtech research. In recognition of the success and positive impact on the Australian medtech sector, the BridgeTech Program was awarded further funding from MTPConnect through the Biomedical Translation Bridge (BTB) Fund for a further 3 years. Learn more at the MTPConnect website.